ABOUT US
Cura Genomics, Inc.™, (CGI), a leading genomic diagnostic and decision-support company, provides physicians with the actionable intelligence they need to dramatically improve health outcomes. Through combined diagnostic solutions that include pharmacogenomics, next-generation sequencing, and therapeutic drug monitoring, CGI is refining therapy management and treatment decisions. From therapy decision support to tumor diagnostics and drug monitoring, CGI delivers the clinical insight physicians need to improve diagnosis and optimize therapy decisions with the goals of preventing therapeutic failure and enhancing patient lives. CGI is taking a multi-tiered approach with the establishment of a planned high-complexity CLIA/CAP certified molecular diagnostic laboratory with a focus on molecular testing in
-
oncology,
-
a broad range of clinical specialties, and
-
research and development.
​
COMPREHENSIVE GENOMIC DIAGNOSTICS
CGI delivers genomic diagnostics that include pharmacogenomics to establish a clear understanding of a patient’s potential drug/drug and drug/gene interactions, molecular profiling tests, including next-generation sequencing to determine key characteristics of a patient’s tumor and therapeutic drug monitoring to ensure safe levels of therapy have been achieved. Physicians can create a safe and effective treatment plan with a single diagnostic company.
ACTIONABLE INTELLIGENCE AND REPORTING
By testing only relevant markers, CGI reports not only show specific diagnostic results but also interpret those results to be immediately actionable. CGI provides proactive and predictive recommendations for effective therapies and evaluates a patient’s metabolic profile to limit severe adverse drug reactions.
CLINICAL IMPLICATIONS AND MONITORING SERVICES
CGI maintains a staff of molecular pathologists, pharmacists, and physicians to discuss the clinical implications of diagnostic results. Additional diagnostics are available to monitor a patient’s response once therapy has begun.
Providing complete patient care solutions by bringing the personalized genomic tests from laboratories to the providers
Bridging the gap between healthcare centers, pharma/biotech manufacturers, pharmacies, and payors
"Cancer therapy PGx has become one of the most important frontiers of personalized cancer therapeutics worldwide" - Da-Yong Lu
OUR SERVICES
Clinical Lab Testing
-
Pharmacogenomics (PGx) Cancer diagnostics
-
Infectious Diseases
-
Drug Compliance Monitoring Therapeutic
-
Drug Monitoring General Chemistry
Research and Development
-
Research and clinical study development
-
Design biomarker discovery studies
-
Assay development and validation Scientific Consultation
Informatics
-
Data Analytics
-
Clinical Interpretation
-
Software Licensing
-
LIMS and EHR Integration EHR Connectivity Solutions
Contract Research
-
Clinical trials test services
-
Assay development and validation, execution and reporting to meet GLP and GCP requirements
-
Investigator support and scientific consultation
Joint Ventures
-
Work with other entities for co-development of IP (tests, software, etc.)
Lab-to-Lab
-
Contract work with other labs
"Now, as a result of genetic and genomic research, the one size fits all strategy is evolving into a more personalized approach called pharmacogenomics." - American Nurse Today
Pharmacogenomics (PGx) tests can play an important role in identifying responders and non-responders to medications, avoiding adverse events, and optimizing drug dose.
​
Pharmacogenomic testing offers individualized prescribing
tailored in accordance with your patient’s metabolic/genetic profile.
Next Generation Sequencing (NGS) is an advanced DNA sequencing technology that allows the rapid sequencing of large stretches of DNA base pairs spanning the entire genome
NGS can be performed on a range of cancer types using samples such as blood, solid tissue, and bone marrow samples
CONTACT US
Questions or comments? Contact us here. Or call us at 1-844-4DNA-CURA